Navigation Links
Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
Date:1/9/2008

SEATTLE, Jan. 9 /PRNewswire/ -- Omeros Corporation announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Omeros. Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Pacific Growth Equities, LLC will be acting as the co- lead manager, and Leerink Swan LLC and Needham & Company, LLC will be acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email: prospectusrequest@list.db.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urol
'/>"/>

Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
2. Pharmos Corporation Completes Initial Closing of Private Placement
3. Pharmos Corporation Announces Board and Management Changes
4. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
11. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood ... sponsor of the 10th Annual World Stem Cell Summit, the ... stakeholders. The 2014 World Stem Cell Summit will be held ... Antonio, Texas . The World ... development of lifesaving cures and therapies, convening the most prominent ...
(Date:11/18/2014)... Brunswick, NJ (PRWEB) November 18, 2014 ... Data Quality and Transparency Reporting solutions, announced today ... gone live using its Consummate Providerâ„¢ solution in ... Providerâ„¢ is a Global, SaaS based, Data Quality ... organizations and their third party Providers improve their ...
(Date:11/18/2014)... , Nov. 18, 2014 PDL BioPharma, Inc. ... in connection with the acquisition of Durata Therapeutics, Inc. ... connection with the termination of PDL,s credit agreement with ... outstanding of $40 million, accrued interest, and prepayment and ... into a structured financing transaction with Durata in which ...
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today the formation of a Medical ... to the Company as it advances the Phase ... the treatment of cutaneous T-cell lymphoma (CTCL), a ...
Breaking Biology Technology:Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6
... WAUKESHA, WI. - RedPrairie Corporation , has ... electronic product code (EPC)-compliant radio frequency identification ... in a real-world environment. The RFID Lab is ... tag placement and readability as they prepare for ...
... , University of Wisconsin - Madison spinout company ... from angel investors in Madison and throughout the state ... motion devices and controllers for nanoscale research and manufacturing. ... used to image, measure, and move objects at the ...
... heard UW-Madison professor Raj Veeramani and Menasha Corp. ... importance of innovation in todays economy at the ... Foundation in northeast Wisconsin. , ,The WIN Foundation ... Council, which is the independent, non-profit science and ...
Cached Biology Technology:RedPrairie Builds RFID Lab - Enables Real-World Testing 2WIN Northeast Wisconsin Chapter Launched for Regions Entrepreneurs 2
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
(Date:11/6/2014)... Except when that predator runs so fast that it essentially ... is the fastest creature on Earth. Some of these half-inch-long ... five miles per hour). The fastest human can do about ... tiger beetle, a person would have to hit 480 miles ... At peak speeds, everything becomes a blur. They can,t gather ...
(Date:11/4/2014)... 2014 – University of Utah engineers developed the first ... fuel produce electricity without needing to ignite the fuel. ... portable electronics, off-grid power and sensors. , A study ... American Chemical Society journal ACS Catalysis . , ... reaction between a fuel and an oxygen-rich source such ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Jet-fueled electricity at room temperature 2
... is the primary component of nursery container substrates in ... widely used organic material is prompting researchers to investigate ... James E. Altland and Charles Krause of the USDA ... Development Center was designed to determine if ground switchgrass ...
... statistics buried within patient records or detailed in newspaper ... patterns, allowing the discovery of trends that were previously ... use of interactive maps and graphs, combined with word ... events like the spread of Swine flu," said Frank ...
... the Braunschweiger Helmholtz-Zentrums fr Infektionsforschung (Helmholtz Center for ... bacterial communities are able to support the degradation ... collaboration of thirteen partners from nine countries. Research ... today at the HZI. The significance of this ...
Cached Biology News:Switchgrass proves viable as nursery container substrate 2Switchgrass proves viable as nursery container substrate 3Visualization of geographic patterns may predict spread of disease 2Improving the degradation of toxic hydrocarbons 2
Request Info...
... 2'-O-Methyltransferase converts Cap 0 (or Cap 0-like) ... 1 structure has been shown to increase ... 50%. This improvement is seen in Cap ... Capping System as well as those Cap ...
Form: Ready to use Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Biology Products: